Compare SONO & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SONO | ALMR |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | 2018 | 2026 |
| Metric | SONO | ALMR |
|---|---|---|
| Price | $13.81 | $26.87 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $19.67 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 243.4K |
| Earning Date | 05-04-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $1,443,276,000.00 | N/A |
| Revenue This Year | $5.04 | N/A |
| Revenue Next Year | $6.53 | N/A |
| P/E Ratio | $27.06 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.12 | $21.58 |
| 52 Week High | $19.82 | $24.58 |
| Indicator | SONO | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 38.54 | N/A |
| Support Level | $12.67 | N/A |
| Resistance Level | $14.76 | N/A |
| Average True Range (ATR) | 0.77 | 0.00 |
| MACD | -0.19 | 0.00 |
| Stochastic Oscillator | 5.86 | 0.00 |
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.